Article
Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2022
Batalini Felipe, Gulhan Doga C, Mao Victor, Tran Antuan, Polak Madeline, Xiong Niya, Tayob Nabihah, Tung Nadine M, Winer Eric P, Mayer Erica L, Knappskog Stian, Lønning Per E, Matulonis Ursula A, Konstantinopoulos Panagiotis A, Solit David B, Won Helen, Eikesdal Hans P, Park Peter J, Wulf Gerburg M
Abstract excerpt
PURPOSE: The identification of patients with homologous recombination deficiency (HRD) beyond BRCA1/2 mutations is an urgent task, as they may benefit from PARP inhibitors. We have previously developed a method to detect mutational signature 3 (Sig3), termed SigMA, associated with HRD from clinical panel sequencing data, that is able to reliably detect HRD from the limited sequencing data derived from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.